Loading...
Καταχωρήθηκε: Παρασκευή 08 Ιαν 2021
Duration of shedding of viable SARS-CoV-2 in severely immunosuppressed  patients with cancer
For most patients with COVID-19, persistently positive nucleic acid 
testing after symptom resolution does not indicate prolonged 
infectiousness. However, accumulating evidence suggests that some 
severely immunocompromised patients may have prolonged shedding of 
viable SARS-CoV-2. One study of 20 patients with a hematologic 
malignancy and COVID-19, 18 of whom had hematopoietic cell 
transplantation or CAR T cell therapy and two with lymphoma, found that 
viable virus could be grown in culture from respiratory samples for up 
to two months after symptom onset. The best way to determine duration of 
isolation for severely immunocompromised patients who have persistently 
positive nucleic acid testing is uncertain. In some cases, information 
about the cycle threshold (Ct) may be incorporated.


REF:  Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of Viable 
SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med 
2020.


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
 

 

Τηλέφωνα Επικοινωνίας:

 

Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)

 

βρείτε μας στο χάρτη

 

Login / Sitemap

 

© Copyright 2015 - 2021 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας